Hermida et al., 2004 - Google Patents
A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in miceHermida et al., 2004
View HTML- Document ID
- 17888021407177633836
- Author
- Hermida L
- Rodrı́guez R
- Lazo L
- Silva R
- Zulueta A
- Chinea G
- López C
- Guzmán M
- Guillén G
- Publication year
- Publication venue
- Journal of virological methods
External Links
Snippet
A gene fragment encoding for the amino acids (aa) 286–426 from the dengue Envelope (E) protein was expressed in Escherichia coli as two forms of fusion proteins. In one case, the E fragment was fused to the first 45 aa of the P64k protein from Neisseria meningitidis (PD2) …
- 102000004169 proteins and genes 0 title abstract description 57
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
- C12N2770/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hermida et al. | A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice | |
| Fahimi et al. | Dengue viruses and promising envelope protein domain III-based vaccines | |
| Putnak et al. | An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model | |
| Men et al. | Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge | |
| Kochel et al. | Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice | |
| Costa et al. | Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence | |
| Ramanathan et al. | Development of a novel DNA SynCon™ tetravalent dengue vaccine that elicits immune responses against four serotypes | |
| Apt et al. | Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen | |
| Srivastava et al. | Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection | |
| JP6018575B2 (en) | Dengue virus recombinant subunit vaccine | |
| US10227385B2 (en) | Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection | |
| Costa et al. | DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice | |
| US6432411B1 (en) | Recombinant envelope vaccine against flavivirus infection | |
| AU758361B2 (en) | Recombinant nonstructural protein subunit vaccine against flaviviral infection | |
| Brandt | From the World Health Organization: development of dengue and Japanese encephalitis vaccines | |
| KR20180137514A (en) | Vaccination compositions and methods against dengue virus in children and young adults | |
| KR20010022452A (en) | Recombinant dimeric envelope vaccine against flaviviral infection | |
| US7947281B2 (en) | Chimeric proteins that induce effects directed against viruses | |
| Zulueta et al. | Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice | |
| JP2016504315A (en) | Compositions, methods of administration and uses for trivalent dengue virus formulations | |
| Rumyantsev et al. | Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys | |
| Hermida et al. | A fragment of the envelope protein from dengue‐1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice | |
| Zulueta et al. | The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs | |
| Wu et al. | Sub-fragments of the envelope gene are highly protective against the Japanese encephalitis virus lethal infection in DNA priming—protein boosting immunization strategies | |
| Zhang et al. | Neutralizing antibodies respond to a bivalent dengue DNA vaccine or/and a recombinant bivalent antigen |